Evidence map›Paper›PMID 37190243›Full record

ArticleCancers2023

Ketevan Ghambashidze, Ramaz Chikhladze, Tamar Saladze, P Jack Hoopes, Fridon Shubitidze

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Ketevan GhambashidzeDepartment of Pathophysiology, Tbilisi State Medical University, Tbilisi 0177, Georgia.ORCID 0000-0002-3845-9306
Ramaz ChikhladzeDepartment of Anatomic Pathology, Tbilisi State Medical University, Tbilisi 0177, Georgia.
Tamar SaladzeDepartment of Anatomic Pathology, Tbilisi State Medical University, Tbilisi 0177, Georgia.
P Jack HoopesGeisel School of Medicine at Dartmouth College, Hanover, NH 03755, USA.
Fridon ShubitidzeGeisel School of Medicine at Dartmouth College, Hanover, NH 03755, USA.ORCID 0000-0001-9674-4810
Tbilisi State Medical University · GEDartmouth College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor microenvironment (TME), where cancer cells reside, plays a crucial role in cancer progression and metastasis. It maintains an immunosuppressive state in many tumors and regulates the differentiation of precursor monocytes into M1 (anti-tumor)- and M2 (pro-tumor)-polarized macrophages, and greatly reduces anticancer drug and nanoparticle delivery. As a result, the effectiveness of recently developed chemo- and/or nanotechnology-mediated immune and magnetic nanoparticle hyperthermia (mNPH) therapies is inhibited significantly. One of the ways to overcome this limitation is to use

Indexed as

cancerE. coli phagelysateimmunotherapymagnetic nanoparticle hyperthermiatumor-associated macrophagestumor microenvironment

Identifiers

PMID37190243
PMCPMC10136591
OpenAlexW4366091140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.